On Sunday evening I took the fourth Tremfya (guselkumab) injection out of the refrigerator. As I carefully opened the box the instructions fell out onto the desk. I thought, hey, I know how to inject a syringe subcutaneously, so I don't need to look at it. But a seed of doubt entered my mind: have I really injected Tremfya correctly?
I couldn’t believe what I read in a letter dated November 21 from Western Health Advantage (WHA), my health insurance provided. They approved my continuation of care request for one more visit in December.I’d already said goodbye to Dr. M and his team at the November appointment. With excitement, I called the Dermatology department to book my last dermatology visit at UC Davis Health. That last appointment, while hard to book, helped me assess my progress and figure out next steps for psoriasis and eczema treatments.
I started my Tremfya (guselkumab) journey on Monday, August 21, 2017. On December 11, after three injections (week 0, 4, 12), I reached that interim endpoint of 16 weeks. Here I evaluate my experience so far with Tremfya, including efficacy, side effects, and how I'm feeling overall. The "verdicts" in this post reflect a moment in time, and certainly are not final.
For much of the last year I looked forward to taking Tremfya (guselkumab) to treat my severe chronic psoriasis. My dermatologist suggested I hold off on the new IL-17A inhibitors until it was FDA approved. Now almost three months into the new treatment I am asking a question I hoped not to need to ask: what’s next?
I wrote this article for the National Psoriasis Foundation as an update to my Treat to Target experience earlier this year. The editor decided to take excerpts from below as a postscript and republish as An ongoing experiment with Treat to Target. See the postscript for a brief week 13 with Tremfya update.